apaziquone tentative trade name indolequinone bioreductive prodrug similar older chemotherapeutic agent mitomycin c hypoxic cells inner surface urinary bladder apaziquone converted active metabolites intracellular reductases active metabolites alkylate dna lead activity preferentially expressed neoplastic cells administration apaziquone directly urinary bladder intravesically drug active metabolite detected plasma systemic side apaziquone applied clinical studies sponsored spectrum pharmaceuticals allergan treatment superficial nonmuscle invasive bladder approximately newly diagnosed patients bladder cancer nonmuscle invasive bladder cancer one million patients united states europe affected disease us food drug administration fda granted fast track review status apaziquone httpsenwikipediaorgwikiapaziquone